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Novelty and Impact 
Ethanol in alcoholic beverages has a causal association with colorectal cancer. Differences in 
associations of alcohol intake with colorectal cancer subtypes defined by the presence of 
somatic mutations in oncogenes BRAF and KRAS are not yet established. In the present study, 
lifetime alcohol intake was associated with increased risks of KRAS+ and BRAF-/KRAS- 
tumors (originating via specific molecular pathways including the traditional adenoma-
carcinoma pathway) but not with BRAF+ tumors, a hallmark of tumor development via the 
‘serrated’ pathway.       
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Abstract 
Ethanol in alcoholic beverages is a causative agent for colorectal cancer. Colorectal cancer is 
a biologically heterogeneous disease, and molecular subtypes defined by the presence of 
somatic mutations in BRAF and KRAS are known to exist. We examined associations 
between lifetime alcohol intake and molecular and anatomic subtypes of colorectal cancer. 
We calculated usual alcohol intake for 10-year periods from age 20 using recalled frequency 
and quantity of beverage-specific consumption for 38,149 participants aged 40-69 years from 
the Melbourne Collaborative Cohort Study. Cox regression was performed to derive hazard 
ratios (HRs) and 95% confidence intervals (CIs) for the association between lifetime alcohol 
intake and colorectal cancer risk. Heterogeneity in the HRs across subtypes of colorectal 
cancer was assessed. A positive dose-dependent association between lifetime alcohol intake 
and overall colorectal cancer risk (mean follow-up=14.6 years; n=596 colon and n=326 rectal 
cancer) was observed (HR = 1.08, 95% CI: 1.04-1.12 per 10 g/day increment). The risk was 
greater for rectal than colon cancer (phomogeneity=0.02). Alcohol intake was associated with 
increased risks of KRAS+ (HR = 1.07, 95% CI: 1.00-1.15) and BRAF-/KRAS- (HR = 1.05, 
95% CI: 1.00-1.11) but not BRAF+ tumors (HR = 0.89, 95% CI: 0.78-1.01; phomogeneity=0.01). 
Alcohol intake is associated with an increased risk of KRAS+ and BRAF-/KRAS- tumors 
originating via specific molecular pathways including the traditional adenoma-carcinoma 
pathway but not with BRAF+ tumors originating via the serrated pathway. Therefore, 
limiting alcohol intake from a young age might reduce colorectal cancer originating via the 
traditional adenoma-carcinoma pathway. 
 
 
 
4 
 
Introduction 
Ethanol in alcoholic beverages is a carcinogen1 that increases the risk of colorectal cancer.2 
Although colorectal cancer is generally referred to as a single, broad disease entity, it is a 
heterogeneous group of diseases in terms of molecular pathology and prognosis.3, 4 A number 
of molecularly defined subtypes of colorectal cancer have been described related to the 
presence of key somatic events including microsatellite instability (MSI), the CpG island 
methylator phenotype (CIMP), chromosomal instability, and somatic mutations in the 
oncogenes BRAF, KRAS and PIK3CA.5 For instance, colorectal cancers with BRAF mutation 
are considered a distinct group3, 6 while a combination of features sets KRAS-mutated 
colorectal cancers apart from tumors harboring neither BRAF nor KRAS mutation.7  
      Smoking has been consistently shown to have differences in associations with the risk of 
specific molecular subtypes of colorectal cancer.8-10 Findings for alcohol thus far have been 
inconsistent: increased risks of MSI-low8 and MSI-high11, 12 colorectal cancer as well as an 
absence of a difference in association with MSI13, 14 or BRAF and CIMP15, 16 subtypes have 
been reported; associations for KRAS or combined BRAF/KRAS subtypes are not available. 
Similarly, uncertainty remains whether alcohol consumption poses a greater risk for rectal 
cancer over colon cancer: mechanistically, this is plausible considering that the rectal mucosa 
is exposed to a greater carcinogenic effect of acetaldehyde due to its higher concentration.17 
In the present study, we examined the associations between lifetime alcohol intake and 
colorectal cancer risk, overall and by subtypes defined by BRAF V600E and KRAS codons 12 
and 13 somatic mutation status, and anatomic location (colon versus rectal), using data from 
the Melbourne Collaborative Cohort Study (MCCS).  
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Materials and Methods  
Study population 
The MCCS is a prospective cohort study of 41,514 people (99.2% aged 40-69 years; 58.9% 
women) recruited during 1990-94 from Melbourne.18 Participants were recruited through the 
electoral rolls (registration to vote is compulsory for adults in Australia), advertisements and 
community announcements in local media (such as television, radio, newspapers). 
Participants attended clinics where demographic, anthropometric, lifestyle and dietary 
information were collected and anthropometric measurements were performed. Participants 
aged <40 (n=194) and 70+ years (n=131) at baseline, with a confirmed cancer diagnosis 
before baseline (n=1,467), missing alcohol consumption data for any age period (n=22), 
reporting implausibly high alcohol intake (n=616) or extreme values of total energy intake 
(<1st percentile and >99th percentile) (n=779), and missing data on any of the covariates 
modelled (n=156) were excluded, leaving 38,149 (91.9% of all participants) eligible for this 
analysis (Fig. 1). The study protocol was approved by the Cancer Council Victoria’s Human 
Research Ethics Committee. Participants gave written informed consent to participate and for 
investigators to obtain access to their medical records. 
 
Baseline data collection 
A structured interview schedule was used at baseline to obtain information on potential risk 
factors including age, sex, country of birth, education, smoking habits, physical activity, and 
previous medical conditions. A 121-item food frequency questionnaire was used to collect 
dietary information.19 Waist circumference was measured using a standard protocol. Baseline 
residential addresses were used to classify participants into quintiles of an area-based 
measure of socioeconomic status.20   
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Assessment of alcohol consumption  
Participants were asked at baseline if they had ever drunk at least 12 alcoholic drinks in a 
year. Those who had (‘non-lifetime abstainers’) were then asked about their usual frequency 
of consumption and usual quantity consumed per drinking occasion for beer, wine and spirits 
separately during 10-year age periods commencing at age 20, up to the decade of their age at 
baseline attendance. Usual intake within each age period in grams per day for each beverage 
type was calculated by multiplying intake frequency by quantity and standard amount of 
alcohol per container using Australian food composition tables.21 The alcohol intake for each 
age period in grams per day was calculated as the sum of intake from the three beverage 
types. The baseline (current) alcohol intake in grams per day was obtained from intake for the 
age period encompassing baseline. Beverage-specific total intakes within age periods were 
summed to obtain total lifetime intakes in grams. The average lifetime alcohol intake in 
grams per day was derived by dividing the total lifetime intake by the total number of days 
within the age intervals up to baseline attendance.  
 
Cohort follow-up and ascertainment of cases and deaths 
Cases and vital status were ascertained through the Victorian Cancer Registry (VCR), the 
Victorian Registry of Births, Deaths and Marriages, the National Death Index and the 
Australian Cancer Database. Incident cases were men and women with a first 
histopathological diagnosis of adenocarcinoma of the colon or rectum during follow-up to 31 
December 2008. Cancer incidence data was coded following the 3rd Revision of the 
International Classification of Diseases for Oncology (ICD-O-3): colon (C18.0, C18.2-18.9) 
and rectum (C19.9, C20.9). Carcinomas of the appendix, and anus and anal canal including 
overlapping lesions of rectum, anus and anal canal, were not included but censored at 
diagnosis. In-situ lesions diagnosed during follow-up were ignored. 
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Tumor molecular characterization and subtype classification 
Archival tumor tissue was sought for all tumors diagnosed in Victoria. Diagnosis was verified 
and pathology was reviewed by a gastrointestinal histopathologist (CR). Tumor DNA was 
tested for the V600E BRAF mutation, which accounts for approximately 90% of BRAF 
mutations in colorectal cancer,22 using a fluorescent allele-specific PCR discrimination 
method as previously described.23 Exon 1 of KRAS was analyzed by direct Sanger 
sequencing.24 Three tumor molecular subtypes were defined as follows: BRAF+, KRAS+ and 
BRAF-/KRAS- (BRAF+/KRAS+ does not occur frequently).  
 
Statistical analysis   
Follow-up began at baseline attendance and continued until diagnosis of first colorectal 
cancer, censoring, death, date of leaving Victoria or 31 December 2008, whichever came 
first. Cox regression25 with age as the time axis was performed to calculate HRs and 95% CIs 
for colorectal cancer overall, by molecular subtypes and by anatomic site (colon versus 
rectum), comparing lifetime alcohol intake with lifetime abstention. The following intake 
categories were used: abstainers (reference category), >0-19 g/day, 20-29 g/day, 30-39 g/day 
and ≥40 g/day. Wald tests from Cox regression models were used to assess linear trends for a 
10 g/day increment in alcohol intake and for intake categories as a continuous measure. To 
test for heterogeneity in the HRs across molecular and anatomic subtypes of colorectal 
cancer, Cox regression models were fitted using a competing risks method.26 Dose-response 
relationships between lifetime alcohol intake (as a continuous variable) and colorectal cancer 
incidence were examined by comparing models that included alcohol as a linear term only 
and as restricted cubic splines (four knots).27 We fitted interaction terms to test for 
differences in associations by attained age (by splitting the data by median age at diagnosis). 
Sub-group analyses by gender were performed.   
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      A causal diagram (directed acyclic graph) and existing evidence were used to determine 
confounding variables to be included in the multivariable-adjusted models. These were sex, 
education (primary school, some high/technical school, completed high/technical school, 
completed tertiary degree/diploma), socioeconomic status (quintiles ranging from most to 
least disadvantaged), smoking (never, former, current), physical activity (none, low, 
moderate, high), total red meat intake (quartiles), energy from food not including alcoholic 
beverages (continuous), dietary fiber intake (continuous) and dietary folate intake 
(continuous), and all models were stratified by country of birth (Australia/New Zealand, 
United Kingdom, Italy, Greece). Because waist circumference might be a consequence rather 
than a cause of alcohol consumption, we fitted models with (continuous) and without 
adjustment for this variable. We considered the model without adjustment for waist 
circumference to be the primary analysis. 
      In the subtype analysis, cases missing tumor molecular data were censored at diagnosis. 
In a sensitivity analysis, all participants diagnosed with any cancer other than colorectal 
cancer were censored at diagnosis. In addition, associations for baseline (‘current’) alcohol 
intake were also assessed. Each model was examined for outliers and influential points.28 
Nested models were compared using the likelihood ratio test.29 Tests based on Schoenfeld 
residuals showed no evidence that proportional hazard assumptions were violated.30 All 
statistical tests were two-sided, and P-values less than 0.05 were considered statistically 
significant. All statistical analyses were performed using Stata 14.1 (StataCorp, College 
Station, TX).  
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Results 
Characteristics of all 38,149 participants and cases by molecular and anatomic subtype are 
given in Table 1. The study had more females (59.5%) than males, and the majority were 
born in Australia, New Zealand or the UK (76.1%) (Table 1). More than half had never 
smoked and only 11% were current smokers. Almost a third of the participants did not 
consume alcohol and about half the participants consumed less than 20 g/day (Table1). Of 
those who consumed alcohol, men reported median intakes of 17.6 g/day, 6.4 g/day and 4.5 
g/day for total alcohol, beer and wine respectively (very few drank spirits), while women 
reported a median alcohol intake of 6.3 g/day.  
By the end of follow-up (average 14.6 years/person), 922 incident cases of colorectal 
cancer were diagnosed (596, 64.6% colon; 326, 35.4% rectum), 1,428 participants had left 
Victoria and 4,153 had died. Molecular pathology data were obtained for 670 (73%) of the 
tumors; Figure 1 shows the reasons why data on BRAF/KRAS status were not obtained. The 
participants missing BRAF/KRAS status were not different in terms of their baseline 
characteristics from those with this information (Supplementary Table 1).  
There were 111 colorectal cancers (16.6%) that had BRAF mutations, 183 (27.3%) 
that had KRAS mutations and 376 (56.1%) that were BRAF-/KRAS-. Of all tumors with 
molecular data, 423 (63.1%) were located in the colon, including 85.6% of the BRAF+ 
tumors, 63.4% of the KRAS+ tumors and 56.4% of the BRAF-/KRAS- tumors. Nearly two-
thirds of the patients with BRAF+ tumors were female while there were more males than 
females that had the other two subtypes (Table 1). BRAF+ tumors were rare for participants 
born in Italy or Greece (Table 1). Compared with patients whose tumors were KRAS+ or 
BRAF-/KRAS-, a higher proportion of patients with BRAF+ tumors were lifetime abstainers 
from alcohol and fewer consumed ≥30 g/day (Table 1).  
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Lifetime alcohol intake and colorectal cancer risk 
These analyses included all 922 cases of colorectal cancer. Lifetime alcohol consumption was 
associated with an increased incidence of colorectal cancer (HR = 1.08, 95% CI: 1.04-1.12 
for a 10 g/day increment, p for trend=<0.001; HR = 1.50, 95% CI: 1.15-1.95 for a lifetime 
intake of ≥40 g/day compared with lifetime abstention; p for trend=0.001) (Table 2). The 
model with the cubic splines fitted no better than a model with a single linear term for 
lifetime intake (p=0.5). This association was significant for males (HR = 1.06, 95% CI: 1.02-
1.11 for a 10 g/day increment, p for trend=0.003) and females (HR = 1.10, 95% CI: 1.00-1.21 
for a 10 g/day increment, p for trend=0.05) (Table 2). For males, a HR of 1.08 (95% CI: 1.03-
1.14, p for trend=0.004) for colorectal cancer was observed for a 10 g/day increment in beer 
intake while the evidence for an association for wine was weaker (HR = 1.07, 95% CI: 0.99-
1.17 for a 10 g/day increment, p for trend=0.09); too few women drank beer to undertake a 
similar comparison. Associations did not change materially when waist circumference was 
included in the models (Supplementary Table 2).  
 
Associations with molecular subtypes of colorectal cancer 
Lifetime alcohol intake was associated with increased incidence of KRAS+ and BRAF-
/KRAS- tumors (HR = 1.07, 95% CI: 1.00-1.15 and HR = 1.05, 95% CI: 1.00-1.11 
respectively, for a 10 g/day increment) but not BRAF+ tumors (HR = 0.89, 95% CI: 0.78-1.01 
for a 10 g/day increment) (phomogeneity=0.01) (Table 3). Using BRAF status alone, a higher 
incidence of BRAF- (HR = 1.06, 95% CI: 1.01-1.11 for a 10 g/day increment) and a lower 
incidence of BRAF+ tumors (HR = 0.89, 95% CI: 0.78-1.01 for a 10 g/day increment) 
associated with lifetime alcohol intake was observed (phomogeneity=0.003) (Table 3). The 
associations between lifetime alcohol intake and the two KRAS molecular subtypes did not 
differ (phomogeneity=0.3) (Table 3). 
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Site-specific associations (colon versus rectum) 
An increment in lifetime alcohol intake by 10 g/day was associated with a greater incidence 
of rectal cancer (HR = 1.08, 95% CI: 1.03-1.14) but not colon cancer (HR = 1.00, 95% CI: 
0.96-1.05) (phomogeneity=0.02) (Table 3). For males, this pattern was observed for beer (HR = 
1.11, 95% CI: 1.03-1.20 for rectal cancer and HR = 1.06, 95% CI: 0.98-1.13 for colon cancer, 
for a 10 g/day increment) and for wine (HR = 1.12, 95% CI: 0.99-1.27 for rectal cancer and 
HR = 1.05, 95% CI: 0.94-1.16 for colon cancer, for a 10 g/day increment) although the HR 
for rectal cancer for wine was not statistically significant (results not shown). However, there 
was no persuasive evidence for a difference in incidence between colon and rectal cancer for 
BRAF- tumors alone (phomogeneity=0.4) (Table 3). There was no evidence of interactions with 
attained age for colon (p = 0.6) or rectal cancer (p = 0.09) when the data were split according 
to median age at diagnosis (≤70 and >70 years).  
 
Sensitivity analysis 
HRs for overall colorectal cancer or molecular and anatomic subtypes did not change when 
individuals diagnosed with any cancer (apart from colorectal cancer) were censored at 
diagnosis (results not shown). In addition, current alcohol intake at baseline was also 
associated with an increased incidence of colorectal cancer (HR = 1.05, 95% CI: 1.01-1.09 
for a 10 g/day increment, p for trend=0.02) but a difference in association between BRAF+, 
KRAS+ and BRAF-/KRAS- subtypes was not observed (phomogeneity=0.2).   
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Discussion 
Our results confirm an association between lifetime alcohol intake and risk of colorectal 
cancer. A greater risk was observed for rectal than for colon cancer in the present analysis. 
Alcohol intake was positively related to risk of BRAF- tumors irrespective of their KRAS 
status but not to risk of BRAF+ tumors. For BRAF- tumors, alcohol intake was positively 
associated with both colon and rectal tumors, but the association was weaker and not 
significant for colon cancer.   
      One of the main strengths of the present study is the availability of alcohol consumption 
data from age 20 especially considering that carcinogenesis is a chronic process. Also, 
abstainers for current intake might be contaminated by quitters. Other strengths include the 
relatively large number of colorectal cancers for which tumor BRAF and KRAS status were 
assessed according to standardized protocols,  the prospective nature of the study, the near 
complete follow-up of cases through the population cancer registry, the low rates of attrition, 
and the availability of a range of demographic, clinical and lifestyle data. Nevertheless, 
several limitations exist: measurement error due to respondents having to summarize their 
frequency and quantity of alcoholic beverage intake for 10-year age intervals into single 
‘usual’ values, potential for present intake to influence recall of past intake and under-
reporting of past intake, residual confounding by unmeasured factors, and the fact that 
alcohol intake could have changed after the baseline assessment. We were unable to obtain 
archival tissue from the primary lesion to establish BRAF/KRAS status for about one quarter 
of the cases. However, this is unlikely to have biased the observed associations because the 
proportions of cases with and without BRAF/KRAS status varied little by ethnicity or sex, 
which were both strongly associated with molecular subtype.31 Also, the possible lower 
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sensitivity of the technique employed to detect KRAS mutation may have contributed to an 
absence of a difference in association between KRAS+ and BRAF-/KRAS- tumors.  
      In a recent meta-analysis, we found a relative risk of 1.49 for colorectal cancer associated 
with long term alcohol intake comparing the highest with the lowest intake category.2 The 
excess risk associated with heavy drinking in the present study for all colorectal cancer is 
similar. Biological mechanisms proposed for alcohol-associated colorectal carcinogenesis 
include effects on carcinogen metabolism and hormone levels,32 direct cellular injury and 
gene mutations in the large intestine caused by acetaldehyde,33 decreased glutathione levels 
and the elimination of free radicals,34 increased cell proliferation in the rectal mucosa17 and 
aldehyde dehydrogenase and alcohol dehydrogenase genetic status which is thought to 
modify the association between alcohol and colorectal cancer.35 The plausible relationship 
between alcohol intake and altered one-carbon metabolism that could result in aberrations in 
DNA methylation with or without epigenetic modifications has been the focus of recent 
investigations.36, 37  
BRAF and KRAS are oncogenes that affect intracellular signaling pathways and are 
associated with global molecular characteristics which cause alterations of gene function on a 
genome-wide scale. For example, BRAF+ is associated with high degree of CIMP38-40 and 
KRAS+ with CIMP-low.39, 41, 42 CIMP is characterized by a propensity for widespread CpG 
island hypermethylation43 and is important for defining a specific etiologic pathway of 
tumorigenesis among colorectal cancers under certain conditions.44 BRAF and KRAS, on the 
other hand, are now part of routine clinical assessments for screening for Lynch syndrome 
and for assessing response to anti-EGFR therapy, respectively, rather than assessment of 
CIMP.45, 46 Colorectal cancers can be divided into two broad subgroups: CIMP-
high/BRAF+/KRAS- and CIMP-low or CIMP-/BRAF-/ KRAS+ or – tumors.3, 4 Substantial 
evidence exists to suggest that CIMP-high (hence BRAF+) colorectal tumors arise through 
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the ‘serrated’ pathway rather than the ‘traditional’ adenoma-carcinoma pathway.44, 47-51 A 
previous analysis using MCCS data had confirmed an association between BRAF+ and 
CIMP+ tumors, and an underlying genetic basis for differential etiologies of colorectal 
cancer.31 The association of lifetime alcohol intake with an increased risk of BRAF- tumors in 
the present study suggests that the effects of alcohol on colorectal cancer development are 
restricted to tumors that arise through the traditional adenoma-carcinoma pathway of 
tumorigenesis. This pathway results in the development of tumors that are predominantly 
microsatellite stable (MSS), CIMP- and frequently harbor KRAS mutations, although the 
Lynch syndrome subtype of tumors demonstrating high levels of MSI are also thought to 
develop via adenoma-carcinoma pathway.4 Our evidence does not suggest that the risk differs 
for the adenoma-carcinoma pathway according to the presence or otherwise of a KRAS 
mutation. In contrast, we observed no positive association between lifetime alcohol intake 
and colorectal cancers that harbored the BRAF V600E somatic mutation, a hallmark of tumor 
development through the ‘serrated’ pathway. Previously, the Nurses’ Health Study has 
reported HRs of 1.36 (95% CI: 0.67-2.74) for BRAF- and 1.05 (95% CI: 0.71-1.56) for 
BRAF+ colon cancer associated with an alcohol intake of ≥15 g/day for women.15 Similar 
findings were reported for participants in the Iowa Women’s Health Study: HRs of 1.19 (95% 
CI: 0.91-1.57) for BRAF- and 0.95 (95% CI: 0.61-1.46) for BRAF+ colorectal cancer 
associated with an intake of >3.4 g/day.16 Neither study observed a dose-dependent 
association between alcohol intake and overall colon15 or colorectal cancer risk.16 Further, a 
recent case-control study reported odds ratios of 1.30 (95% CI: 0.91-1.85) for adenomas and 
0.99 (95% CI: 0.68-1.47) for serrated polyps associated with an alcohol intake of ≥14 
drinks/week.52 
      While published studies which predominantly used current intake have not established a 
clear difference in risk for the associations of colon and rectal cancer with alcohol,53 the 
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European Prospective Investigation into Cancer and Nutrition reported HRs of 1.12 (95% CI: 
1.06-1.18) for rectal and 1.05 (95% CI: 1.00-1.11) for colon cancer for a 15 g/day increment 
in lifetime alcohol intake but did not report a formal test result comparing HRs.54 We have 
shown a greater risk of rectal than colon cancer associated with alcohol in line with the 
explanation for greater exposure of distal colorectal mucosa to the carcinogenic effects of 
acetaldehyde than the proximal part.17 We are unable to confirm whether there is a definitive 
site-specific difference in risks and found little evidence suggestive of a site-specific 
difference in risks for BRAF- tumors. Further epidemiologic evidence is needed to confirm a 
gradient of increasing associations from proximal to the distal colorectum for alcohol intake 
along with further mechanistic explanations for this putative relationship.                         
      In summary, we have confirmed that the association between alcohol intake and the risk 
of colorectal cancer might be limited to specific molecular pathways including the 
‘traditional’ adenoma-carcinoma pathway, the etiologic pathway for the majority of 
colorectal cancer.44 Therefore, limiting alcohol intake from a young age might help prevent 
occurrence of a sizeable proportion of colorectal cancer.         
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Figure legend 
 
Figure 1. Flow diagram showing selection of participants 
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Table 1. Baseline characteristics of participants and colorectal cancer cases in the Melbourne Collaborative Cohort Study 
 
All participants 
(n=38,149) 
All cases 
(n=922) 
Colorectal cancer cases   
  According to tumor molecular subtype1, 2 According to anatomic location1 
  
BRAF+ 
 (n=111) 
KRAS+ 
(n=183) 
BRAF-/ 
KRAS- 
(n=376) 
Colon 
(n=596) 
Rectum 
(n=326) 
Age at baseline, mean (SD), years 55.2 (8.6) 60.1 (7.6) 61.9 (6.8) 60.5 (7.5) 59.5 (7.7) 60.1 (7.8) 59.9 (7.3) 
Sex, n (%)      
Male  15,462 (40.5) 468 (50.8) 38 (11.2) 101 (29.6) 202 (59.2) 282 (60.3) 186 (39.7) 
Females 22,687 (59.5) 454 (49.2) 73 (22.2) 82 (24.9) 174 (52.9) 314 (69.2) 140 (30.8) 
Country of birth, n (%)      
Australia/New Zealand/UK 29,046 (76.1) 696 (75.5) 99 (19.9) 133 (26.8) 265 (53.3) 457 (65.7) 239 (34.3) 
Italy/Greece 9,103 (23.9) 226 (24.5) 12 (6.9) 50 (28.9) 111 (64.2) 139 (61.5) 87 (38.5) 
Education, n (%)      
Primary school 7,337 (19.2) 210 (22.8) 17 (10.5) 46 (28.6) 98 (60.9) 131 (62.4) 79 (37.6) 
Some high/technical school 14,492 (38.0) 355 (38.5) 42 (16.5) 71 (28.0) 141 (55.5) 232 (65.3) 123 (34.7) 
Completed high/technical school  7,891 (20.7) 200 (21.7) 30 (21.1) 35 (24.7) 77 (54.2) 137 (68.5) 63 (31.5) 
Completed tertiary degree/diploma 8,429 (22.1) 157 (17.0) 22 (19.5) 31 (27.4) 60 (53.1) 96 (61.2) 61 (38.8) 
Smoking, n (%)      
Never 22,171 (58.1) 470 (51.0) 62 (18.2) 93 (27.4) 185 (54.4) 317 (67.5) 153 (32.5) 
Former 11,794 (30.9) 353 (38.3) 33 (12.9) 72 (28.1) 151 (59.0) 217 (61.5) 136 (38.5) 
Current 4,184 (11.0) 99 (10.7) 16 (21.6) 18 (24.3) 40 (54.1) 62 (62.6) 37 (37.4) 
Lifetime alcohol intake (g/day), n (%)      
Abstainer 11,067 (29.0) 251 (27.2) 38 (21.2) 40 (22.4) 101 (56.4) 175 (69.7) 76 (30.3) 
>0-19 19,453 (51.0) 427 (46.3) 51 (16.7) 91 (29.8) 163 (53.5) 283 (66.3) 144 (33.7) 
20-29 3,220 (8.4) 91 (9.9) 14 (20.0) 17 (24.3) 39 (55.7) 54 (59.3) 37 (40.7) 
30-39 1,816 (4.8) 54 (5.9) 1 (2.4) 13 (30.9) 28 (66.7) 28 (51.9) 26 (48.1) 
≥40 2,593 (6.8) 99 (10.7) 7 (9.5) 22 (29.7) 45 (60.8) 56 (56.6) 43 (43.4) 
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1Row percentages given. 
2For individuals with data on tumor molecular subtype.  
SD, standard deviation. 
 
 
 
 
 
 
 
 
 
Physical activity, n (%)    
None 8,431 (22.1) 218 (23.6) 27 (16.2) 39 (23.3) 101 (60.5) 129 (59.2) 89 (40.8) 
Low 7,721 (20.2) 175 (19.0) 20 (16.9) 37 (31.4) 61 (51.7) 111 (63.4) 64 (36.6) 
Moderate 13,464 (35.3) 347 (37.7) 40 (15.9) 76 (30.3) 135 (53.8) 241 (69.5) 106 (30.5) 
High 8,533 (22.4) 182 (19.7) 24 (17.9) 31 (23.1) 79 (59.0) 115 (63.2) 67 (36.8) 
Energy intake from food, mean (SD), kJ/day 8,777 (3,041) 9,003 (3,125) 8,588 (2,869) 9,450 (3,293) 8,935 (3,046) 9,116 (3,184) 8,797 (3,008) 
Waist circumference,  mean (SD), cm 85.4 (12.9) 89.4 (13.1) 86.8 (12.8) 90.3 (11.8) 90.0 (13.1) 88.9 (13.6) 90.3 (12.0) 
Tumor molecular subtype        
BRAF+ - 111 (12.0) - - - 95 (85.6) 16 (14.4) 
KRAS+ - 183 (19.9) - - - 116 (63.4) 67 (36.6) 
BRAF-/KRAS- - 376 (40.8) - - - 212 (56.4) 164 (43.6) 
Missing - 252 (27.3) - - - 173 (68.6) 79 (31.4) 
24 
 
Table 2. Hazard ratios (HR) and 95% confidence intervals (CI) for colorectal cancer according to lifetime alcohol intake for participants in the 
Melbourne Collaborative Cohort Study 
 Cases (%) 
Person 
years 
Multivariable-adjusted1 p for trend2 
HR (95% CI) 
All      
For a 10 g/day increment in alcohol intake  922 (100) 558,871 1.08 (1.04-1.12) <0.001 
Alcohol intake categories (g/day)     0.001 
Lifetime abstainer 251 (27.2) 166,390 1  
>0–19 427 (46.3) 283,526 1.03 (0.87-1.22)  
20-29  91 (9.9) 46,384 1.24 (0.95-1.60)  
30-39 54 (5.9) 26,167 1.24 (0.90-1.70)  
≥40  99 (10.7) 36,404 1.50 (1.15-1.95)  
      
Men      
For a 10 g/day increment in alcohol intake 468 (100) 221,107 1.06 (1.02-1.11) 0.003 
Alcohol intake categories (g/day)     0.02 
Lifetime abstainer 67 (14.3) 32,048 1  
>0–19 196 (41.9) 104,316 1.01 (0.76-1.34)  
20-29  70 (15.0) 31,598 1.20 (0.85-1.69)  
30-39 45 (9.6) 20,776 1.15 (0.78-1.69)  
≥40  90 (19.2) 32,369 1.38 (0.99-1.92)  
     
For a 10 g/day increment in beer intake 468 (100) 221,107 1.08 (1.03-1.14) 0.004 
For a 10 g/day increment in wine intake 468 (100) 221,107 1.07 (0.99-1.17) 0.09 
      
Women    
For a 10 g/day increment in alcohol intake 454 (100) 337,764 1.10 (1.00-1.21) 0.05 
Alcohol intake categories (g/day)     0.1 
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1Adjusted for sex (for men and women combined), education, socioeconomic status, smoking, physical activity, energy intake from food, dietary 
fiber, dietary folate and total red meat, and stratified by country of birth. 
2Wald test from Cox regression models assessing linear trends for a 10 g/day increment in alcohol intake and for intake categories as a 
continuous measure.
Lifetime abstainer 184 (40.5) 134,342 1  
>0–19 231 (50.9) 179,211 1.00 (0.81-1.23)  
20-29  21 (4.6) 14,786 1.14 (0.72-1.83)  
30-39 9 (2.0) 5,390 1.46 (0.74-2.90)  
≥40  9 (2.0) 4,035 2.00 (1.01-3.96 )  
     
For a 10 g/day increment in wine intake 454 (100) 337,750 1.12 (0.99-1.26) 0.07 
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Table 3. Hazard ratios (HR) and 95% confidence intervals (CI) for colorectal cancer for a 10 g/day increment in lifetime alcohol intake by tumor 
molecular subtype and anatomic location for participants in the Melbourne Collaborative Cohort Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Adjusted for sex, education, socioeconomic status, smoking, physical activity, energy intake from food, dietary fiber, dietary folate and total red 
meat, and stratified by country of birth. 
2Test of homogeneity.    
 Cases (%) 
For a 10 g/day increment in alcohol intake 
HR (95% CI)1 p value2 
Tumor molecular subtype     
BRAF/KRAS subtype 670 (100.0)   0.01 
BRAF+ 111 (16.6) 0.89 (0.78-1.01)  
KRAS+ 183 (27.3) 1.07 (1.00-1.15)  
BRAF-/KRAS- 376 (56.1) 1.05 (1.00-1.11)  
     
BRAF  subtype 676 (100.0)   0.003 
BRAF+ 113 (16.7) 0.89 (0.78-1.01)  
BRAF- 563 (83.3) 1.06 (1.01-1.11)  
     
KRAS  subtype 683 (100.0)   0.3 
KRAS+ 189 (27.7) 1.07 (1.00-1.15)  
KRAS- 494 (72.3) 1.03 (0.98-1.08)  
     
Anatomic location 922 (100.0)   0.02 
For all colorectal cancer     
Colon 596 (64.6) 1.00 (0.96-1.05)  
Rectum 326 (35.4) 1.08 (1.03-1.14)  
     
For  BRAF- colorectal cancer     
Colon 330 (58.6) 1.03 (0.98-1.10) 0.4 
Rectum 233 (41.4) 1.07 (1.00-1.14)  
